Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.
Hsu-Heng YenPei-Yuan SuYa-Huei ZengI-Ling LiuSiou-Ping HuangYu-Chun HsuYang-Yuan ChenChia-Wei YangShun-Sheng WuKun-Ching ChouPublished in: PloS one (2020)
Despite a higher rate of pruritus among patients with ESRD, GLE/PIB-based therapy achieved similarly high SVR rates among patients with and without ESRD.